Aspen to sell European thrombosis business for €641.9m

  • 📰 BDliveSA
  • ⏱ Reading Time:
  • 36 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 18%
  • Publisher: 63%

대한민국 뉴스 뉴스

The proceeds of the sale to US pharmaceutical group Mylan will be used to reduce debt, Aspen says

Africa’s largest drugmaker Aspen Phamacare has agreed to sell its European thrombosis business to US group Mylan for €641.9m .

The proceeds of the sale of business, which focuses on anticoagulant drugs, will be used to pay down debt, Aspen said.Aspen had R33.4bn in net debt at the end of December, and said in March that it was reviewing its businesses in Europe. Aspen said on Tuesday the sale of the European thrombosis business supports its strategy of continuing to reshape the group towards a greater concentration of revenue in emerging markets.

In morning trade on Tuesday, Aspen’s share had jumped 8.91% to R146, putting it on track for its best one-day performance in about two weeks. The group’s share has risen 22.5% so far in 2020, giving the group a market capitalisation of R66.6bn on Tuesday morning.

 

귀하의 의견에 감사드립니다. 귀하의 의견은 검토 후 게시됩니다.
이 소식을 빠르게 읽을 수 있도록 요약했습니다. 뉴스에 관심이 있으시면 여기에서 전문을 읽으실 수 있습니다. 더 많은 것을 읽으십시오:

 /  🏆 12. in KR

대한민국 최근 뉴스, 대한민국 헤드 라인

Similar News:다른 뉴스 소스에서 수집한 이와 유사한 뉴스 기사를 읽을 수도 있습니다.

Third Chinese company has ‘fat finger’ issue, but analyst cries wolfShenzhen Changfang Group said shareholder accidentally sold 16,000 shares by imputing wrong ticker
출처: BDliveSA - 🏆 12. / 63 더 많은 것을 읽으십시오 »

Third Chinese company has ‘fat finger’ issue, but analyst cries wolfShenzhen Changfang Group said shareholder accidentally sold 16,000 shares by imputing wrong ticker
출처: BDliveSA - 🏆 12. / 63 더 많은 것을 읽으십시오 »